The FDA drew a hard line on gene therapy Monday, fully liberating Intellia’s CRISPR pipeline from clinical holds while simultaneously enforcing a rigorous Phase 3 barrier for uniQure’s Huntington’s program—effectively ending hopes for a “surrogate-only” approval path in neurodegeneration. Elsewhere, Roche’s fenebrutinib became the first BTK inhibitor to clear all Phase 3 hurdles in both relapsing and progressive MS, and United Therapeutics delivered blockbuster pulmonary arterial hypertension data. The policy landscape also intensified as the ITC launched a probe into Chinese biotech practices and midsize biotechs formed a coalition to fight Most-Favored-Nation pricing.

Top Story: FDA Rejects uniQure’s Early Path; Intellia CRISPR Hold Fully Lifted

What Happened: In a split-screen day for gene therapy, shares of uniQure (QURE) plummeted 40% after the FDA rejected its current Phase 1/2 data package for AMT-130 in Huntington’s disease, demanding a randomized, sham-controlled Phase 3. Conversely, Intellia Therapeutics (NTLA) shares rose as the FDA fully lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 CRISPR trials following safety alignment on enhanced liver monitoring protocols.

The uniQure Rejection

AMT-130 Program:

AMT-130 is an AAV5-based gene therapy for Huntington’s disease that:

• Delivers micro-RNA targeting mutant huntingtin protein
• Requires neurosurgical implantation via burr hole in skull
• Aims to reduce toxic protein accumulation in brain
• Has accumulated three years of Phase 1/2 data

What uniQure Proposed:

The company sought approval based on:

• Phase 1/2 safety and biomarker data
• Comparison to external natural history controls
• Surrogate endpoint measures (huntingtin protein levels, brain imaging)
• Accelerated approval pathway

What FDA Demanded:

The agency requires:

• Randomized, prospective Phase 3 trial
• Sham-controlled design (placebo patients undergo mock surgery)
• Direct comparison rather than natural history controls
• Clinical outcome measures, not just biomarkers

Why This Matters:

The FDA’s insistence on sham-controlled trials for invasive neurosurgical gene therapies represents a fundamental shift in regulatory approach. Despite three years of positive data versus external controls, the agency is refusing to accept surrogate-only evidence for complex neurodegenerative conditions.

The Sham Surgery Control Challenge:

Sham-controlled trials in neurosurgery are ethically and operationally complex:

Ethical considerations:

• Subjecting patients to invasive surgery (skull penetration, anesthesia risk) without therapeutic benefit
• Informed consent requirements
• Patient willingness to accept sham surgery possibility

Operational challenges:

• Enrollment difficulty (patients may refuse sham surgery risk)
• Higher costs (surgical procedures for all participants)
• Extended timelines (larger trials, longer follow-up needed)
• Institutional review board scrutiny

uniQure’s Path Forward:

The company plans a Type B meeting with FDA in Q2 2026 to discuss:

• Phase 3 trial design parameters
• Acceptable sham surgery protocols
• Clinical endpoint selection
• Sample size and statistical power
• Feasibility assessment

Timeline Implications:

A Phase 3 sham-controlled trial would:

• Require 2-3 years for enrollment
• Need 2-3 years of follow-up for clinical outcomes
• Push potential approval to 2029 or later
• Require substantial additional capital

Strategic Options:

uniQure may consider:

• Pursuing EU/UK approval with more flexible regulatory standards
• Seeking partnership to fund Phase 3 development
• Exploring M&A or licensing options
• Pivoting resources to other pipeline programs

The Intellia Liberation

What Changed:

The FDA fully lifted clinical holds on:

• MAGNITUDE: Phase 3 trial in ATTR cardiomyopathy
• MAGNITUDE-2: Additional ATTR-CM trial

Why Holds Were Placed:

Previous concerns centered on:

• Elevated liver enzymes in some patients
• Questions about CRISPR editing safety in cardiac disease
• Need for enhanced monitoring protocols

Resolution:

FDA and Intellia aligned on:

• Enhanced liver monitoring protocols: More frequent enzyme testing
• Patient selection criteria: Exclusion of patients with ejection fraction <25%
• Short-term steroid protocols: To manage potential immune responses
• Safety reporting requirements: Standardized adverse event tracking

What This Enables:

Intellia can now:

• Resume enrollment in MAGNITUDE trials
• Accelerate patient recruitment to reclaim timeline
• Compete with rivals in in vivo CRISPR space
• Target 1H 2027 enrollment completion

ATTR Cardiomyopathy Context:

Transthyretin amyloid cardiomyopathy (ATTR-CM) results from misfolded protein deposits in heart tissue, causing:

• Progressive heart failure
• Conduction abnormalities
• High mortality (median survival 2-5 years untreated)

Current Treatment Landscape:

• Tafamidis (Pfizer’s Vyndamax): Stabilizes TTR protein, approved therapy generating >$3 billion annually
• RNA interference: Patisiran, inotersen reduce TTR production
• CRISPR editing: Intellia’s approach permanently knocks out TTR gene

Intellia’s Competitive Advantage:

One-time CRISPR editing offers potential advantages:

• Permanent TTR reduction vs. chronic medication
• No daily pills or periodic infusions
• Durable benefit from single treatment

Commercial Opportunity:

If approved (projected 2028):

• Peak sales potential: $2-4 billion
• First in vivo CRISPR therapy approval
• Platform validation for additional indications
• ATTR-CM market growing with increased awareness

Near-Term Risks:

Despite hold lift, concerns remain:

• Liver safety caveats may restrict addressable population
• Patient selection criteria (EF <25% exclusion) reduces market
• Long-term safety monitoring requirements
• Competition from established therapies and other CRISPR companies

What to Watch: MAGNITUDE enrollment velocity, additional safety data disclosures, competitive CRISPR programs, and potential partnerships or commercial preparations.

The Broader Gene Therapy Signal

FDA’s Bifurcated Approach:

Monday’s actions reveal the FDA’s dual strategy:

Willing to support:

• One-time editing platforms with manageable safety profiles
• Programs implementing enhanced monitoring
• Technologies addressing serious unmet needs with appropriate controls

Unwilling to accept:

• External natural history controls for complex neurodegenerative diseases
• Surrogate-only evidence for invasive therapies
• Accelerated approval without robust efficacy demonstration

Implications for CNS Gene Therapy Sector:

All programs targeting brain diseases via invasive delivery must now anticipate:

• Sham-controlled trial requirements
• Extended development timelines
• Substantially higher development costs
• Recruitment challenges

Commissioner Makary’s Position:

Last week’s comments about a gene therapy “drilling a burr hole” with no observed benefit—interpreted as referring to AMT-130—underscore the agency’s skeptical stance toward invasive neurosurgical gene therapies lacking compelling efficacy evidence.

Impact on Huntington’s Disease Programs:

With uniQure forced into multi-year Phase 3, capital may rotate toward:

Antisense oligonucleotides (ASOs):

• Less invasive (intrathecal injection vs. neurosurgery)
• Reversible dosing (can stop if issues arise)
• Potentially faster regulatory path

Small molecule oral modifiers:

• Non-invasive administration
• Traditional drug development pathways
• May have shorter relative timeline to market

Re-Rating of CNS Gene Therapy Assets:

Investors are recalculating probability of success for any rare disease asset lacking prospective, blinded control arms. Programs relying on external controls face increased regulatory risk.

Roche Fenebrutinib: BTK Inhibitor Breakthrough

What Happened: Roche reported pivotal Phase 3 FENhance 1 results showing fenebrutinib achieved a 51% reduction in annualized relapse rates in relapsing multiple sclerosis versus teriflunomide over at least 96 weeks.

The BTK Class Context:

Bruton’s tyrosine kinase (BTK) inhibitors target B-cell function, addressing both relapsing and progressive MS biology. However, earlier BTK inhibitors faced challenges:

• Evobrutinib (Merck): Failed Phase 3
• Tolebrutinib (Sanofi): Liver toxicity concerns
• Other BTK programs: Safety signals limiting development

Fenebrutinib’s Differentiation:

Liver safety profile:

• Liver enzyme elevations comparable to active control (teriflunomide)
• No excess hepatotoxicity signals
• Potentially resolves class-wide safety concerns

Efficacy demonstration:

• 51% reduction in annualized relapse rate vs. active comparator
• First BTK inhibitor to meet all primary endpoints in relapsing MS
• Data in both relapsing and progressive forms

Multiple Sclerosis Treatment Landscape:

Current therapies include:

Injectable:

• Interferon beta formulations
• Glatiramer acetate

Oral:

• Fingolimod (sphingosine-1-phosphate receptor modulator)
• Teriflunomide (pyrimidine synthesis inhibitor)
• Dimethyl fumarate

Infusion:

• Natalizumab (integrin blocker)
• Ocrelizumab (anti-CD20)
• Ofatumumab (anti-CD20)

Market Opportunity:

Approximately 1 million U.S. patients with MS, with majority having relapsing-remitting form. BTK inhibitors offering:

• Oral convenience
• Brain-penetrant B-cell modulation
• Activity in both relapsing and progressive disease
• Acceptable safety profile

Competitive Positioning:

If approved (mid-year filing expected, 2027 approval potential):

• Challenges anti-CD20 therapies (Ocrevus, Kesimpta) requiring infusions or injections
• Offers oral convenience vs. infusion therapies
• First BTK inhibitor with clean liver safety
• May capture share from existing oral therapies with less effective profiles

Full Data Presentation:

Complete results will be presented at American Academy of Neurology (AAN) 2026 meeting, providing detailed safety, efficacy, and subgroup analyses.

What to Watch: AAN presentation details, regulatory filing timing, pricing strategy, and payer coverage positioning.

United Therapeutics: Ralinepag PAH Breakthrough

What Happened: United Therapeutics reported Phase 3 ADVANCE OUTCOMES trial results showing ralinepag achieved a 55% reduction in the risk of clinical worsening in pulmonary arterial hypertension, with 80% of patients on dual background therapy at baseline.

Ralinepag Profile:

• Mechanism: Oral prostacyclin receptor agonist
• Dosing: Once-daily administration
• Differentiation: First oral prostacyclin demonstrating this durability level with once-daily dosing

Pulmonary Arterial Hypertension Background:

PAH is characterized by:

• Elevated pulmonary artery pressure
• Progressive right heart failure
• High morbidity and mortality
• Approximately 40,000-50,000 U.S. patients

Prostacyclin Pathway:

Prostacyclin causes:

• Pulmonary vasodilation
• Anti-proliferative effects on vascular smooth muscle
• Anti-thrombotic effects

PAH pathophysiology includes prostacyclin deficiency, making this pathway therapeutically valuable.

Current PAH Treatment:

Prostacyclin therapies:

• IV epoprostenol: Continuous infusion, gold standard efficacy but complex administration
• Subcutaneous treprostinil: Injection site pain
• Inhaled prostacyclins: Multiple daily administrations
• Oral selexipag (J&J’s Uptravi): Twice-daily, $2+ billion annually

Combination therapy: Most patients require multiple medications targeting different pathways (prostacyclin, endothelin, nitric oxide).

Ralinepag’s Competitive Advantages:

vs. Injectable prostacyclins:

• Oral administration (no infusion pump, no injection sites)
• Better quality of life
• Lower infection risk

vs. Uptravi (selexipag):

• Once-daily dosing (vs. twice-daily)
• 55% clinical worsening risk reduction demonstrates robust efficacy
• May offer differentiated safety/tolerability

The 80% Dual Background Therapy Context:

Most trial patients (80%) were already on two other PAH therapies (typically endothelin receptor antagonist + phosphodiesterase-5 inhibitor). Demonstrating 55% additional risk reduction on top of dual therapy validates ralinepag as important add-on treatment.

Market Opportunity:

Peak sales potential: $1-2 billion

• PAH market growing with increased diagnosis
• Combination therapy standard of care
• Oral convenience drives adoption
• Once-daily dosing preferred vs. twice-daily Uptravi

NDA Filing:

United Therapeutics plans submission in second half 2026, targeting 2027 approval. The company already has:

• Commercial infrastructure from existing PAH portfolio (Remodulin, Tyvaso, Orenitram)
• KOL relationships
• Payer contracting experience

Strategic Significance:

Ralinepag reinforces United Therapeutics’ dominant position in PAH market. Combined with recent GSK acquisition of 35Pharma for $950 million (activin pathway asset), the PAH competitive landscape is reshaping rapidly toward oral therapies with differentiated mechanisms.

What to Watch: NDA submission timing, detailed safety data, pricing strategy, and Uptravi competitive response.

Policy & Regulatory Developments

ITC Probes China Biotech Practices

What Happened: The U.S. International Trade Commission initiated a fact-finding investigation into Chinese state support and pricing practices in biotechnology, covering:

• Genomic sequencing
• Synthetic biology
• Active pharmaceutical ingredient (API) manufacturing

Investigation Scope:

The ITC will examine:

• Chinese government subsidies and support for biotech sector
• Pricing practices that may undercut U.S. competitors
• Market access barriers for U.S. companies in China
• Intellectual property concerns
• Supply chain dependencies

Public Hearing:

Scheduled for May 2026, allowing industry stakeholders to testify on:

• Competitive impacts of Chinese biotech practices
• Supply chain vulnerabilities
• National security implications
• Recommended policy responses

Context:

The investigation represents escalation in U.S.-China biotech decoupling efforts beyond existing BIOSECURE Act framework, which restricts certain Chinese biotech companies from U.S. government contracts.

Potential Outcomes:

• Recommendations for additional restrictions on Chinese biotech companies
• Tariffs or trade measures
• Enhanced screening of Chinese biotech investments
• Supply chain reshoring incentives

Industry Impact:

U.S. biotechs face two-front pressure:

• Competition from subsidized Chinese companies
• Domestic pricing pressures from MFN policies

Midsize Biotechs Form MFN Coalition

What Happened: Ten domestic biotechnology companies—including Alnylam, BioMarin, and Neurocrine—launched the Midsized Biotech Alliance of America (MBAA) to oppose the Most Favored Nation drug pricing policy.

MBAA Argument:

The coalition warns MFN pricing “could destroy biotech innovation” because:

• Midsize biotechs lack diversified portfolios to absorb pricing cuts
• International reference pricing reduces U.S. revenues funding R&D
• Smaller companies face existential risk vs. large pharma that can absorb impacts
• Innovation pipeline at risk if development becomes uneconomic

Advocacy Gap:

MBAA fills space between:

• PhRMA: Represents large pharmaceutical companies
• BIO: Broader biotech trade association

Midsize biotechs (single-product or limited portfolios generating $500M-$3B revenue) face unique vulnerabilities from blanket pricing mandates that larger diversified pharma can absorb.

Most Favored Nation Policy:

Proposal would cap U.S. drug prices at lowest international reference price, typically from European countries with government price negotiations. For many drugs, this represents 40-60% reduction from current U.S. pricing.

Political Context:

State of the Union address featured President Trump urging Congress to codify MFN deals, though few new healthcare policy details were provided beyond general “Great Healthcare Plan” rhetoric.

Congress Approves $315M ALS Funding

What Happened: Congress approved historic $315 million in federal ALS (amyotrophic lateral sclerosis) research funding for 2026.

Timing:

Coincides with VectorY Therapeutics dosing first patient in PIONEER-ALS trial targeting TDP-43 protein, one of key pathological features in majority of ALS cases.

ALS Research Landscape:

ALS is universally fatal neurodegenerative disease with:

• Median survival 2-5 years from diagnosis
• Approximately 30,000 U.S. patients
• Limited effective therapies (riluzole, edaravone provide modest benefit)
• Multiple failed clinical trials

Increased federal funding supports:

• Basic research into disease mechanisms
• Clinical trial networks
• Biomarker development
• Translational research

Oncology & Rare Disease Updates

Ascendis Pharma YUVIWEL Launch Analysis

Post-approval analysis suggests YUVIWEL (navepegritide) could capture significant achondroplasia market share within 18 months due to:

• Once-weekly dosing vs. BioMarin’s daily Voxzogo injections
• Clinical data showing benefits beyond linear growth (muscle strength, body proportionality, leg bowing reduction)
• Fresh market entrant without incumbent inertia

Base case: 15-20% market share by end of 2026, expanding to 30-40% by 2027 if switching behavior materializes.

VERAXA Biotech Merger Approval

Shareholders approved merger with Voyager Acquisition Corp at February 27 EGM. Combined entity will trade on NASDAQ under ticker VRXA, focusing on:

• Bispecific antibody-drug conjugates
• T-cell engagers
• Novel cancer immunotherapies

Oncolytics Biotech Trial Launch

Launched REO 033 randomized Phase 2 study in second-line KRAS-mutant, microsatellite stable (MSS) metastatic colorectal cancer, building on February’s Fast Track designation. Preliminary data expected by year-end.

LongBio Pharma: Anti-IgE Superiority Data

Announced head-to-head Phase 2 superiority against Novartis’s Xolair (omalizumab) in chronic spontaneous urticaria, demonstrating 860-fold greater IgE binding affinity.

Significance:

If Phase 3 confirms results, LP-003 would become first new anti-IgE drug launched globally in over 20 years. Xolair generates billions annually across multiple allergic indications. BLA submission to China’s NMPA planned by Q3 2026.

Corporate Developments

Royalty Pharma Asia Expansion

Appointed Kenneth Sun (ex-Morgan Stanley) as SVP and Head of Asia, effective May 2026, to spearhead expansion into $130+ billion Asian drug royalty market.

Strategic Rationale:

Chinese innovators increasingly out-license to Western pharmaceutical companies. $130 billion in Chinese out-licensing deal value in 2025 represents massive royalty opportunity as these products generate sales.

IQVIA / Charles River Integration

IQVIA’s agreement to acquire select discovery assets from Charles River Labs expected to close Q2 2026, adding:

• Five in vitro drug discovery sites
• Small molecule AI platform
• Additional discovery capabilities

BioAtla Distress

Announced 70% workforce reduction and formal strategic review process to explore asset sales. The company reported just $7.1 million cash at year-end and faces ongoing Nasdaq listing review.

Represents financial distress requiring immediate action—asset sales, partnerships, or restructuring to conserve remaining capital.

March PDUFA Calendar

March 6:

• BMS Sotyktu (deucravacitinib): Psoriatic arthritis label expansion; if approved, becomes first TYK2 inhibitor for PsA
• Lantheus LNTH-2501: NET imaging agent

March 16:

• Aldeyra Reproxalap: Dry eye disease (third FDA submission attempt)

March 20:

• Rhythm Imcivree (setmelanotide): Acquired hypothalamic obesity; potential 5,000-10,000 patient U.S. market

March 24:

• GSK Linerixibat: Cholestatic pruritus in primary biliary cholangitis

March 28:

• Rocket Kresladi: LAD-I gene therapy

Strategic Themes

The Sham Control Re-Rating

uniQure’s rejection serves as proxy for entire gene therapy sector. The FDA’s insistence on sham surgery controls despite three years of positive external control data signals fundamental shift in accelerated approval calculus for invasive CNS therapies.

Impact: Investors recalculating probability of success for any rare disease asset lacking prospective, blinded control arms.

BTK Renaissance

Roche’s fenebrutinib data revitalizes a class many had written off. Comparable liver safety to teriflunomide removes key objection. Institutional investors now reassessing brain-penetrant B-cell modifiers that can address progressive MS biology.

PAH Market Reshaping

Multiple developments transforming pulmonary arterial hypertension landscape:

• United Therapeutics’ ralinepag: 55% risk reduction, once-daily oral
• GSK’s $950M acquisition of 35Pharma: Next-generation activin inhibitor
• Shift toward oral therapies with differentiated mechanisms

Merck’s Winrevair franchise (activin pathway, $1.4B in 2024) faces emerging competition from multiple angles.

China Decoupling Accelerates

ITC investigation combined with MBAA formation signals two-front policy battle:

• Containing Chinese biotech competition
• Protecting domestic midsize innovators from pricing pressures

Expect continued legislative activity targeting API supply chains and genomic data flows.

Frequently Asked Questions

Q: Why did FDA approve Intellia but reject uniQure if both are gene therapies?

Different safety and efficacy contexts. Intellia’s CRISPR editing showed manageable liver enzyme elevations addressable through enhanced monitoring protocols. uniQure’s AMT-130 requires invasive neurosurgery with FDA demanding sham-controlled trials rather than accepting external control comparisons for Huntington’s disease—a complex, slowly progressive condition where surrogate endpoints are questioned.

Q: What is a sham surgery control and why is it controversial?

Sham surgery control involves subjecting placebo patients to surgical procedure (anesthesia, incision, potentially skull penetration) without delivering therapeutic intervention. Controversial because: exposes patients to surgical risks without therapeutic benefit, raises ethical concerns about informed consent, and faces enrollment challenges as patients may refuse participation knowing sham surgery possibility.

Q: Can uniQure succeed with Phase 3 sham-controlled trial?

Operationally challenging but possible. Success depends on: designing ethically acceptable sham procedure, enrolling sufficient patients despite surgery risks, demonstrating clear clinical benefit (not just biomarkers), and securing funding for expensive multi-year trial. Company exploring feasibility in Q2 2026 Type B meeting with FDA.

Q: Why is fenebrutinib’s liver safety important for BTK inhibitors?

Earlier BTK inhibitors (evobrutinib, tolebrutinib) faced liver toxicity concerns limiting development. Fenebrutinib showing liver enzyme elevations comparable to active control (teriflunomide) rather than excess hepatotoxicity suggests class-wide safety concern may be molecule-specific rather than mechanism-related. This resurrects BTK inhibitor opportunity in MS.

Q: How significant is ralinepag’s 55% risk reduction?

Highly significant given 80% of patients were already on dual background therapy. Demonstrating substantial additional benefit on top of two other PAH medications validates ralinepag as important combination therapy option. Once-daily oral dosing provides convenience advantage over twice-daily Uptravi, potentially capturing market share from $2+ billion selexipag franchise.

Q: What does ITC investigation mean for US biotech companies?

Two potential impacts: (1) Restrictions on Chinese biotech companies may reduce competition but also limit partnership opportunities and manufacturing options. (2) Investigation findings may inform tariffs or trade measures affecting supply chains. US biotechs must balance competitive protection desires against supply chain dependencies on Chinese API manufacturing.

Q: Why form separate midsize biotech coalition instead of joining existing groups?

Midsize biotechs ($500M-$3B revenue, limited product portfolios) face unique vulnerabilities from blanket pricing mandates. Large pharma (PhRMA members) have diversified portfolios absorbing pricing pressures. Small early-stage biotechs (many BIO members) lack marketed products affected by pricing. MBAA represents companies at existential risk from MFN pricing destroying economics of single/limited product franchises funding R&D.

Q: Is the gene therapy sector in crisis after uniQure rejection?

Not crisis but regulatory reality check. FDA supporting gene therapies with appropriate controls and manageable risks (Intellia hold lift demonstrates this). However, invasive CNS therapies relying on external controls face heightened scrutiny. Sector must adapt expectations: anticipate sham-controlled trials for neurosurgical approaches, longer timelines, higher costs. Well-designed programs with compelling efficacy will succeed.

About BioMed Nexus

BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma.

Get the daily brief delivered before market open — Subscribe at biomednexus.com

Pro members access institutional analysis including scenario modeling, competitive positioning frameworks, and probability-weighted outcomes.

Explore Pro Membership →

This analysis is for informational purposes and does not constitute investment advice. All information verified as of March 3, 2026.